Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis

被引：0
|
作者：
Kita, Kanako [1 ]
Imai, Yasutomo [1 ,2 ]
Nagai, Makoto [1 ]
Natsuaki, Masaru [1 ]
Kanazawa, Nobuo [1 ]
机构：
[1] Hyogo Med Univ, Dept Dermatol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan
[2] Imai Adult & Pediat Dermatol, Osaka, Japan
来源：
JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY | 2023年 / 6卷 / 03期
基金：
日本学术振兴会;
关键词：
D O I：
10.1002/cia2.12282
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Dupilumab treatment reduced serum SCCA2 levels in patients with atopic dermatitis. Interestingly, even though the skin eruptions had not yet fully disappeared, serum SCCA2 levels were reduced well to below normal by the administration of dupilumab.
引用
收藏
页码：100 / 101
页数：2
相关论文
共 50 条
  • [21] Dupilumab: a milestone in the treatment of atopic dermatitis
    Tsianakas, Athanasios
    Staender, Sonja
    LANCET, 2016, 387 (10013): : 4 - 5
  • [22] Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis
    Silverberg, Jonathan, I
    Rubini, Norma P. M.
    Pires, Mario C.
    Rossi, Ana B.
    Zhang, Annie
    Chen, Zhen
    Levit, Noah A.
    Chao, Jingdong
    Shumel, Brad
    Bego-Le Bagousse, Gaelle
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (05): : 1279 - +
  • [23] Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis
    Fowler, Emilie
    Rosen, Jordan
    Lev-Tov, Hadar
    Yosipovitch, Gil
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (10) : 899 - 900
  • [24] Corneal Perforation in Patients Under Treatment With Dupilumab for Atopic Dermatitis
    Phylactou, Maria
    Jabbour, Samir
    Ahmad, Sajjad
    Vasquez-Perez, Alfonso
    CORNEA, 2022, 41 (08) : 981 - 985
  • [25] Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer
    Tanczosova, Milena
    Hugo, Jan
    Gkalpakiotis, Spyridon
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [26] Neutropenia on dupilumab in patients with atopic dermatitis
    Pathmarajah, Piru
    Corso, Roberto
    Salam, Amr
    Woolf, Richard
    Smith, Catherine
    Pink, Andrew
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 83 - 83
  • [27] Long-term Dupilumab treatment up to 100 weeks reduces serum biomarkers in patients with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Bissonette, Robert
    Deleuran, Mette
    Harel, Sivan
    McDonald, Robert
    Shumel, Brad
    Rossi, Ana B.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 168 - 168
  • [28] Prognostic value of SCCA2 isoform in NSCLC patients
    Jan, Kulpa
    Wojcik, E.
    Ska, Kami J.
    Einarsson, R.
    Kowalska, M.
    Migas, B.
    TUMOR BIOLOGY, 2006, 27 : 80 - 80
  • [29] SERUM HISTIDINE LEVELS IN ATOPIC DERMATITIS PATIENTS
    ZASLOW, L
    DERBES, VJ
    SOUTHERN MEDICAL JOURNAL, 1970, 63 (09) : 1000 - &
  • [30] Long-term dupilumab treatment for 100 weeks reduces serum TARC and total IgE in patients with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Harel, S.
    Chen, Z.
    Shumel, B.
    Rossi, A. B.
    ALLERGY, 2020, 75 : 27 - 28
12345